Intra-Cellular Therapies Inc $ 19.35 0.42 (2.22%)
Volume:
593,622
Avg Vol (1m):
846,480
Market Cap $:
1.30 Bil
Enterprise Value $:
860.14 Mil
P/E (TTM):
0.00
P/B:
2.97
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 19.58 | ||
| Equity-to-Asset | 0.89 | ||
| Debt-to-Equity | 0.05 | ||
| Debt-to-EBITDA | -0.14 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 13.05 | ||
| Beneish M-Score | 201.12 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -14545.63 | ||
| Net Margin % | -14011.98 | ||
| ROE % | -57.34 | ||
| ROA % | -48.11 | ||
| ROC (Joel Greenblatt) % | -803.52 | ||
| 3-Year Revenue Growth Rate | -50 | ||
| 3-Year EBITDA Growth Rate | -1.5 | ||
| 3-Year EPS without NRI Growth Rate | 0.1 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.97 | ||
| PS Ratio | 1074.99 | ||
| EV-to-EBIT | -5.15 | ||
| EV-to-EBITDA | -5.17 | ||
| EV-to-Revenue | 751.87 | ||
| Current Ratio | 14.83 | ||
| Quick Ratio | 14.79 | ||
| Days Inventory | 7358.19 | ||
| Days Sales Outstanding | 431.04 | ||
| Days Payable | 58156.67 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.98 | ||
| Earnings Yield (Greenblatt) % | -19.35 |